Report Information More information from: https ://www.wis eguyreports .com/reports /495859
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016 Report / Search Code: WGR495859
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 30 April, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016’, provides an overview of the B-Cell Non-Hodgkin Lymphoma pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of B-Cell NonHodgkin Lymphoma - The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlis ts all their major and minor projects - The report as s es s es B-Cell Non-Hodgkin Lymphoma therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for B-Cell NonHodgkin Lymphoma Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding B-Cell NonHodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Introduction 8 B-Cell Non-Hodgkin Lymphoma Overview 9 Therapeutics Development 10 B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 12 B-Cell Non-Hodgkin Lymphoma - Therapeutics under Inves tigation by Univers ities /Ins titutes 22 B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 23 B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 27 B-Cell Non-Hodgkin Lymphoma - Products under Inves tigation by Univers ities /Ins titutes 53 B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 55 B-Cell Non-Hodgkin Lymphoma - Therapeutics As s es s ment 170 Drug ProďŹ les 202 B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 657 B-Cell Non-Hodgkin Lymphoma - Dormant Projects 1015 B-Cell Non-Hodgkin Lymphoma - Dis continued Products 1028 B-Cell Non-Hodgkin Lymphoma - Product Development Miles tones 1033 Appendix 1040 Lis t of Tables Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016 35 Number of Products under Development for B-Cell Non-Hodgkin Lymphoma Comparative Analys is , H1 2016 36 Number of Products under Development by Companies , H1 2016 38 Number of Products under Development by Companies , H1 2016 (Contd..1) 39 Number of Products under Development by Companies , H1 2016 (Contd..2) 40 Number of Products under Development by Companies , H1 2016 (Contd..3) 41 Number of Products under Development by Companies , H1 2016 (Contd..4) 42 Number of Products under Development by Companies , H1 2016 (Contd..5) 43 Number of Products under Development by Companies , H1 2016 (Contd..6) 44 Number of Products under Development by Companies , H1 2016 (Contd..7) 45 Number of Products under Development by Companies , H1 2016 (Contd..8) 46 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 47 Comparative Analys is by Late Stage Development, H1 2016 48 Comparative Analys is by Clinical Stage Development, H1 2016 49 Comparative Analys is by Early Stage Development, H1 2016 50 Comparative Analys is by Unknown Stage Development, H1 2016 51 Products under Development by Companies , H1 2016 52 Products under Development by Companies , H1 2016 (Contd..1) 53 Products under Development by Companies , H1 2016 (Contd..2) 54 Products under Development by Companies , H1 2016 (Contd..3) 55 Products under Development by Companies , H1 2016 (Contd..4) 56 Products under Development by Companies , H1 2016 (Contd..5) 57 Products under Development by Companies , H1 2016 (Contd..6) 58 Products under Development by Companies , H1 2016 (Contd..7) 59 Products under Development by Companies , H1 2016 (Contd..8) 60 Products under Development by Companies , H1 2016 (Contd..9) 61 Products under Development by Companies , H1 2016 (Contd..10) 62 Products under Development by Companies , H1 2016 (Contd..11) 63 Products under Development by Companies , H1 2016 (Contd..12) 64 Products under Development by Companies , H1 2016 (Contd..13) 65 Products under Development by Companies , H1 2016 (Contd..14) 66 Products under Development by Companies , H1 2016 (Contd..15) 67 Products under Development by Companies , H1 2016 (Contd..16) 68 Products under Development by Companies , H1 2016 (Contd..17) 69 Products under Development by Companies , H1 2016 (Contd..18) 70 Products under Development by Companies , H1 2016 (Contd..19) 71 Products under Development by Companies , H1 2016 (Contd..20) 72 Products under Development by Companies , H1 2016 (Contd..21) 73 Products under Development by Companies , H1 2016 (Contd..22) 74 Products under Development by Companies , H1 2016 (Contd..23) 75 Products under Development by Companies , H1 2016 (Contd..24) 76 Products under Development by Companies , H1 2016 (Contd..25) 77 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 78 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 (Contd..1) 79 B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016 80
B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 82 B-Cell Non-Hodgkin Lymphoma 83 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 86 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 90 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma Limited, H1 2016 95 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 104 B-Cell Non-Hodgkin Lymphoma 105 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 2016 111 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 2016 113 B-Cell Non-Hodgkin Lymphoma 2016 114 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 117 B-Cell Non-Hodgkin Lymphoma 2016 118 B-Cell Non-Hodgkin Lymphoma 119 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 126 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 130 B-Cell Non-Hodgkin Lymphoma 131 B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma 138 B-Cell Non-Hodgkin Lymphoma 139 B-Cell Non-Hodgkin Lymphoma
- Pipeline by AbbVie Inc., H1 2016 81 - Pipeline by Acetylon Pharmaceuticals , Inc., H1 2016 - Pipeline by Actinium Pharmaceuticals , Inc., H1 2016 - Pipeline by ADC Therapeutics Sarl, H1 2016 84 - Pipeline by Affimed Therapeutics AG, H1 2016 85 - Pipeline by Altor BioScience Corporation, H1 2016 -
Pipeline Pipeline Pipeline Pipeline
by by by by
Amgen Inc., H1 2016 87 arGEN-X BV, H1 2016 88 Ariad Pharmaceuticals , Inc., H1 2016 89 Arrien Pharmaceuticals , LLC, H1 2016
-
Pipeline Pipeline Pipeline Pipeline Pipeline
by by by by by
Arvinas , Inc., H1 2016 91 As tellas Pharma Inc., H1 2016 92 As tex Pharmaceuticals , Inc., H1 2016 93 As traZ eneca Plc, H1 2016 94 Aurigene Dis covery Technologies
-
Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline
by by by by by by by by by
Bayer AG, H1 2016 96 BeiGene, Ltd., H1 2016 97 BIND Therapeutics , Inc., H1 2016 98 Bio-Path Holdings , Inc., H1 2016 99 Biocon Limited, H1 2016 100 Biogenomics Limited, H1 2016 101 Biothera, Inc., H1 2016 102 Bluebird bio, Inc., H1 2016 103 Boehringer Ingelheim GmbH, H1 2016
- Pipeline by Bris tol-Myers Squibb Company, H1 2016 -
Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline
by by by by by by
Calithera Bios ciences , Inc., H1 2016 106 Celgene Corporation, H1 2016 107 Cell>Point, L.L.C., H1 2016 108 Celldex Therapeutics , Inc., H1 2016 109 Celltrion, Inc., H1 2016 110 Cellular Biomedicine Group, Inc., H1
- Pipeline by Coherus BioSciences , Inc., H1 2016 112 - Pipeline by Cons tellation Pharmaceuticals , Inc., H1 - Pipeline by Corners tone Pharmaceuticals , Inc., H1 - Pipeline by CTI BioPharma Corp., H1 2016 115 - Pipeline by Curis , Inc., H1 2016 116 - Pipeline by Cyclacel Pharmaceuticals , Inc., H1 2016 - Pipeline by Dynavax Technologies Corporation, H1 - Pipeline by eFFECTOR Therapeutics , Inc., H1 2016 -
Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline
by by by by by by by
Eis ai Co., Ltd., H1 2016 120 Eli Lilly and Company, H1 2016 121 EpiZ yme, Inc., H1 2016 122 Erytech Pharma SA, H1 2016 123 F. Hoffmann-La Roche Ltd., H1 2016 124 Genentech, Inc., H1 2016 125 Genor BioPharma Co., Ltd., H1 2016
-
Pipeline Pipeline Pipeline Pipeline
by by by by
Genos co, H1 2016 127 Gilead Sciences , Inc., H1 2016 128 GlaxoSmithKline Plc, H1 2016 129 Hutchis on MediPharma Limited, H1 2016
- Pipeline by Idera Pharmaceuticals , Inc., H1 2016 -
Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline Pipeline
by by by by by by by
IGF Oncology, LLC., H1 2016 132 Immune Des ign Corp., H1 2016 133 ImmunoGen, Inc., H1 2016 134 Immunomedics , Inc., H1 2016 135 Immunovaccine, Inc., H1 2016 136 Incyte Corporation, H1 2016 137 Infinity Pharmaceuticals , Inc., H1 2016
- Pipeline by Inflection Bios ciences Limited, H1 2016 - Pipeline by JHL Biotech, Inc., H1 2016 140
B-Cell Non-Hodgkin Lymphoma - Pipeline by Johns on & Johns on, H1 2016 141 B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 142 B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016 143 B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics , Inc., H1 2016 144 B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 145 B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 146 B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H1 2016 147 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2016 148 B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H1 2016 149 B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016 150 B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H1 2016 151 B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016 152 B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 153 B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016 154 B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals , Inc., H1 2016 155 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 156 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics , Inc., H1 2016 157 B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016 158 B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H1 2016 159 B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016 160 B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016 161 B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics , LLC, H1 2016 162 B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 163 B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 164 B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2016 165 B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics , Inc., H1 2016 166 B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 167 B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H1 2016 168 B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 169 B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics , Inc., H1 2016 170 B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016 171 B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals , Inc., H1 2016 172 B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics , Inc., H1 2016 173 B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016 174 B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals , Inc., H1 2016 175 B-Cell Non-Hodgkin Lymphoma - Pipeline by Res piratorius AB, H1 2016 176 B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 177 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 178 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016 179 B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics , Inc., H1 2016 180 B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016 181 B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 182 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics , Inc., H1 2016 183 B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals , Inc., H1 2016 184 B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics , Inc., H1 2016 185 B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 186 B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2016 187 B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 188 B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics , Inc., H1 2016 189 B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 190 B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 191 B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H1 2016 192 B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics , Inc., H1 2016 193 B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2016 194 As s es s ment by Monotherapy Products , H1 2016 195 As s es s ment by Combination Products , H1 2016 196 Number of Products by Stage and Target, H1 2016 198 Number of Products by Stage and Mechanis m of Action, H1 2016 213 Number of Products by Stage and Route of Adminis tration, H1 2016 224 Number of Products by Stage and Molecule Type, H1 2016 226 B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates , H1 2016 682
B-Cell Non-Hodgkin Lymphoma - Dormant Projects , H1 2016 1040 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 1041 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 1042 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016 1043 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016 1044 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016 1045 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016 1046 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016 1047 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016 1048 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016 1049 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016 1050 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016 1051 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016 1052 B-Cell Non-Hodgkin Lymphoma - Dis continued Products , H1 2016 1053 B-Cell Non-Hodgkin Lymphoma - Dis continued Products (Contd..1), H1 2016 1054 B-Cell Non-Hodgkin Lymphoma - Dis continued Products (Contd..2), H1 2016 1055 B-Cell Non-Hodgkin Lymphoma - Dis continued Products (Contd..3), H1 2016 1056 B-Cell Non-Hodgkin Lymphoma - Dis continued Products (Contd..4), H1 2016 1057 Lis t of Figures Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016 35 Number of Products under Development for B-Cell Non-Hodgkin Lymphoma Comparative Analys is , H1 2016 36 Number of Products under Development by Companies , H1 2016 37 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 47 Comparative Analys is by Late Stage Development, H1 2016 48 Comparative Analys is by Clinical Stage Development, H1 2016 49 Comparative Analys is by Early Stage Products , H1 2016 50 As s es s ment by Monotherapy Products , H1 2016 195 Number of Products by Top 10 Targets , H1 2016 197 Number of Products by Stage and Top 10 Targets , H1 2016 197 Number of Products by Top 10 Mechanis m of Actions , H1 2016 212 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 212 Number of Products by Routes of Adminis tration, H1 2016 223 Number of Products by Stage and Routes of Adminis tration, H1 2016 223 Number of Products by Top 10 Molecule Types , H1 2016 225 Number of Products by Stage and Top 10 Molecule Types , H1 2016 225
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349